Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Future Oncology (London, England)
|
October 12, 2021
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Amer M Zeidan, Tehseen Salimi, Robert S Epstein
Journal of Comparative Effectiveness Research
|
November 19, 2013
Integrating new approaches for clinical development: translational research and relative effectiveness
Jean-Pierre Lehner, Robert S Epstein, Tehseen Salimi
Journal of Comparative Effectiveness Research
|
November 19, 2013
Integrating scientific and real-world evidence within and beyond the drug development process
Robert S Epstein, Jaan Sidorov, Jean-Pierre Lehner, et al.
Expert Review of Anticancer Therapy
|
August 7, 2025
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence
Amer M Zeidan, Ruizhi Zhao, Robert S Epstein, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
The Early Engagement Model in Product Development: Linking "Proof of Concept" to "Proof of Medical Value"
Sheikh Usman Iqbal, Tehseen Salimi, John Dunlop, et al.
Journal of Comparative Effectiveness Research
|
November 19, 2013
A framework for pharmaceutical value-based innovations
Tehseen Salimi, Jean-Pierre Lehner, Robert S Epstein, et al.
The Oncologist
|
February 6, 2026
Third-line treatment decision-making for mCRC: a cross-sectional survey of US community physicians
Christopher Cann, Sophia Zhao, Nadeem Khan, et al.
Advances in Therapy
|
February 10, 2017
When People with Opioid-Induced Constipation Speak: A Patient Survey
Robert S Epstein, J Russell Teagarden, Ali Cimen, et al.
Therapeutic Advances in Hematology
|
February 23, 2026
Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents
Amer M Zeidan, Ruizhi Zhao, Jon G Tepsick, et al.
Therapeutic Advances in Hematology
|
August 2, 2024
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
Amer M Zeidan, Kate Perepezko, Tehseen Salimi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Future Oncology (London, England)
|
October 12, 2021
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Amer M Zeidan, Tehseen Salimi, Robert S Epstein
Journal of Comparative Effectiveness Research
|
November 19, 2013
Integrating new approaches for clinical development: translational research and relative effectiveness
Jean-Pierre Lehner, Robert S Epstein, Tehseen Salimi
Journal of Comparative Effectiveness Research
|
November 19, 2013
Integrating scientific and real-world evidence within and beyond the drug development process
Robert S Epstein, Jaan Sidorov, Jean-Pierre Lehner, et al.
Expert Review of Anticancer Therapy
|
August 7, 2025
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence
Amer M Zeidan, Ruizhi Zhao, Robert S Epstein, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
The Early Engagement Model in Product Development: Linking "Proof of Concept" to "Proof of Medical Value"
Sheikh Usman Iqbal, Tehseen Salimi, John Dunlop, et al.
Journal of Comparative Effectiveness Research
|
November 19, 2013
A framework for pharmaceutical value-based innovations
Tehseen Salimi, Jean-Pierre Lehner, Robert S Epstein, et al.
The Oncologist
|
February 6, 2026
Third-line treatment decision-making for mCRC: a cross-sectional survey of US community physicians
Christopher Cann, Sophia Zhao, Nadeem Khan, et al.
Advances in Therapy
|
February 10, 2017
When People with Opioid-Induced Constipation Speak: A Patient Survey
Robert S Epstein, J Russell Teagarden, Ali Cimen, et al.
Therapeutic Advances in Hematology
|
February 23, 2026
Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents
Amer M Zeidan, Ruizhi Zhao, Jon G Tepsick, et al.
Therapeutic Advances in Hematology
|
August 2, 2024
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
Amer M Zeidan, Kate Perepezko, Tehseen Salimi, et al.
Page
of 2